STOCKS TELEGRAPH

Author: ST Staff

  • How Has The Xeriant Stock Appreciated 43%?

    How Has The Xeriant Stock Appreciated 43%?

    In Tuesday’s session, Xeriant Inc. (OTCPk: XERI) rose 42.54 percent to $0.285 and has been trading between $0.21 and $0.299. Xeriant stock gained over 761% in the past 12 months, reaching a high of $0.58 with $80.91M of market cap. As the company announced to share recent developments, XERI stock price surged.

    Are recent developments going to be updated by XERI?

    Holding and operating company Xeriant, Inc. (d.b.a. Xeriant Aerospace) participates actively in Advanced Air Mobility (“AAM”). As the aerospace industry transitions to more sustainable, efficient, and autonomous operations, AAM is a crucial technology.

    As part of AAM, the economy will be able to access more aerial services and grow applications based on aircraft with vertical takeoff and landing capabilities (VTOL) that help facilitate point-to-point passenger and cargo transportation. XERI’s headquarters are located at Florida Atlantic University’s Research Park in Boca Raton, Florida, next to the Boca Raton Airport.

    A press release for Xeriant, Inc. was recently sent out. In its press advisory, XERI outlined plans to hold a press conference at which it would announce recent noteworthy events. Approximately mid-June is the tentative date for the press conference.

    Furthermore,

    Previously Xeriant (XERI) announced that its subsidiary, Xeriant Europe, had begun testing one of Movychem’s “green” fire protectors branded Retacell. Retacell’s fire protection capabilities are highlighted in several presentation videos on XERI’s YouTube channel. In fact, these videos demonstrate the unique capabilities of this technology in extreme conditions, and those interested can also view a demonstration video on that channel.

  • How Did The Santhera (SPHDF) Stock Skyrocket In The Last Session, Jumping 51%?

    Santhera Pharmaceuticals Holding Limited (OTCPK: SPHDF) closed at $3.7000 after increasing 51.02%, bringing its market cap to $13.54M. Recently, SPHDF stock traded 16.40K shares, a high volume compared to its average daily volume of 4.07K. SPHDF stock rose after a positive and statistically highly significant study concluded.

    What was the purpose of the study?

    Santhera is a Swiss specialty pharmaceutical company dedicated to identifying and developing new medicines for unmet medical needs in the field of rare neuromuscular diseases and respiratory diseases. The SPHDF has the exclusivity for all indications of vamorolone, a first-in-class dissociative steroid with a unique mechanism of action, which has been extensively studied as an alternative to standard corticosteroids in patients with DMD. The SPHDF has licensed exclusive North American rights to its first approved product, Raxone (idebenone), to Chiesi Group for the treatment of Leber’s hereditary optic neuropathy (LHON).

    In a study known as VISION-DMD, Santhera and ReveraGen BioPharma, Inc yesterday announced positive results.

    • Multiple efficacy endpoints were met in the study, suggesting vamorolone is an effective treatment option for patients with DMD and that it is safe and well tolerable as well.
    • VISION-DMD is a pivotal Phase 2b study designed to demonstrate the efficacy and safety of vamorolone in the treatment of DMD in comparison with placebo and prednisone (active control).
    • A 24-week double-blind study of 121 ambulant boys with DMD received vamorolone or placebo in the first 24 weeks.
    • Further safety and tolerability data will be collected during a second study period of 24 weeks in which all participants are treated with either of the two dose levels of vamorolone.

    Results of the study showed that:

    Vamorolone scored higher than placebo in the study across multiple secondary endpoints. Vamorolone has been proven to be effective at dosages ranging from 2 to 6 mg/kg/day, based on clinical trials.

  • How Did The RYPPF Stock Rise 52%?

    The creator of urban athletic apparel, RYU Apparel Inc. (OTCQB: RYPPF) saw its stock price rise 52.20% to $0.1003 during the last trading session which raised its market cap to $19.53M.

    RYU stock currently has 194.67M shares outstanding vs 62.85M float. RYPPF’s stock rose in the absence of current news, but recently released an update that may have contributed to the increase.

    What was that update about?

    As an award winning urban athletic brand engineered for active lifestyles, RYU or Respect Your Universe is an award winning apparel and accessories line. To facilitate optimal human performance, RYPPF provides fit, comfort, and durability without compromising on quality.

    CEO Cesare Fazari gave an update on RYU Apparel recently.

    Corporate Update in Brief:

    • In the last quarter, RYU has concentrated on integrating COO Robert Blair’s new corporate strategy, as well as on the hiring of six team members.
    • As a result of these hires, new divisions like women design, ecommerce, product strategy, and brand management have been formed.
    • With a comprehensive plan for implementing Mr. Blair’s strategy and cultivating key industry relationships in addition to building inventory, launching new products, and forming new partnerships, management believes that RYU is poised for positive future growth starting in Q4 2021.
    • Due to its current financing position, RYPPF will be able to carry out its corporate strategy.
    • A loss of market confidence and unfavorable market conditions have caused RYPPF to suspend the previously announced convertible debenture financing.
    • In order to boost growth plans with much bigger inventory orders, RYPPF will consider the best financial options as it gains more strength, trust, and sales momentum. 

    Business prospects:

    It’s only a matter of time until the Canada Skateboard Collaboration is released, and RYPPF soon will be launching a new campaign introducing bags, uniforms, and commercial apparel. RYU Apparel (RYPPF) is launching a multi-faceted marketing campaign in anticipation of a Fall 2021 release of its apparel collaboration, which will be the official partner of the NFL Alumni Academy.

  • How Did The Ainos (AIMD) Stock Take A Leap Of 52%?

    The market cap of Ainos, Inc. (OTCPINK: AIMD) grew to $204.83M on Tuesday after rising 51.58% on the day to close the session at $1.44. There were 49.56K shares of Ainos stock traded on the day, a volume which was greater than its average daily volume of 24.81K shares.  As a result of a rebranding, AIM’s stock price has increased.

    What is AIMD’s rebranding strategy?

    Ainos formerly known as Amarillo Biosciences, Inc. is a Texas corporation. As a diversified healthcare company, AIMD focuses on pharmaceutical and biotechnology research and development. To combat disease and enhance the body’s ability to heal, AIMD aims to introduce novel products that actively stimulate and rejuvenate the human body.

    Currently, Ainos’ products include COVID-19 (SARS CoV2 Antigen Rapid Test), pneumonia, vaginitis, and helicobacter pylori test kits for point-of-care testing. There are offices of AIMD in Taiwan and the United States.

    Ainos received the approval of FINRA (“the Financial Industry Regulatory Authority”) for the change from the Company’s previous name to “Ainos, Inc.” and “AIMD” as the Company’s new ticker symbol.

    Since May 24, Ainos’ common stock has been trading under the symbol “AIMD”, and its new CUSIP number is 00902F105. As a result of these changes, AIMD announced in April 21, 2021 that a securities purchase transaction had been successfully closed with Cayman Islands corporation Ainos, Inc. (“Investor” or “Ainos KY”).

    Moving forward:

    Ainos (AIMD) has also signed a consulting agreement with Donohoe Advisory Associates LLC for help evaluating the listing requirements of national securities exchanges in the United States.

  • SNLRF Stock Skyrocketed 133% Last Session, Why?

    The price of Sentinel Resources Corp. (OTCPink: SNLRF) rose 132.75 percent to $0.2402 at the close yesterday. Sentinel stock volume was 4,423 compared to trading of 18900 shares on average. SNLRF stock gained following the share consolidation process.

    Why SNLRF has been consolidating?

    Sentinel is a Canadian company focused on acquiring and exploring mines with world-class potential for precious metals. In addition to New South Wales and Australia, SNLRF has gold and silver projects in British Columbia and Australia. SNLRF’s guiding principles focus on acquiring strategic exploration properties in mining-friendly jurisdictions with a history of mining, minimizing capital and operational costs during exploration times, and acquiring properties at a low cost.

    Sentinel recently announced its intention to consolidate its outstanding and issued common shares at the proportion of three (3) pre-consolidated shares to one (1) post-consolidated share.

    • SNLRF is consolidating to generate greater investor interest, improve trading liquidity, and facilitate future financings.
    • A total of 28,075,264 common shares are currently issued and outstanding for SNLRF.
    • With the Consolidation, SNLRF’s outstanding shares will reduce to 9,358,421 shares.

    What SNLRF needs to execute its consolidation plan?

    In accordance with its article of incorporation, Sentinel (SNLRF) will not need to obtain shareholder approval for the consolidation. In order for SNLRF to consolidate, the TSX Venture Exchange must approve it.

  • Did Anything Boost SDIPF Stock Last Trading?

    Stock in Frasers Group plc (OTC: SDIPF) closed up 101.50% to $8.08 in the last trading session. In the session, Frasers stock price remained unchanged at $8.08 against its previous close of $4.01, while 8.5K shares were traded. News of its attempt to acquire a larger company sent SPIDF stock price soaring.

    SDIPF was interested in what?

    The Frasers Group distributes apparel, footwear, and equipment for sports and leisure through department stores, shops, and online through a number of subsidiaries. In sum, SDIPF comprises five segments: Premium Lifestyle, Rest of World Retail, UK Sports Retail, Wholesale & Licensing, European Retail. Aside from sports and leisure clothing sale and distribution, SDIPF takes part in the licensing of sports equipment, clothing, and footwear. In addition to its own brand, SDIPF offers products from third parties.

    Mike Ashley, a billionaire entrepreneur and the founder of Frasers Group, is rumored to be picking up fashion retailer Hugo Boss to buy it for $3.9 billion.

    • Sports Direct, Jack Wills, and Evans Cycles owner SDIPF already owns 15.2% of Hugo Boss.
    • SDIPF’s CEO may be considering a bid for more than €3.2bn (£2.7bn, $3.9bn) for the entire company, reported the Telegraph, citing a German publication.
    • SDIPF, which has been acquiring Hugo Boss shares in recent months, has previously said it plans to be a “supportive shareholder.”
    • Earlier this year, SDIPF increased its stake in Hugo Boss for the second time, increasing it to 10.1% in June 2020 after disclosing an initial holding of 5.1% earlier that month.

    How does SDIPF intend to use the acquisition?

    The Frasers Group (SDIPF) said at the time that it saw Hugo Boss as a long-term partner and believed in its future growth.

    With his House of Fraser and Flannels brands, Mike Ashley is looking to sell more upmarket goods alongside his other retail brands.

  • Do You Know Why Emmaus (EMMA) Stock Jumped Last session?

    Shares of a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, Emmaus Life Sciences, Inc. [OTC:EMMA] rose 1.85% to $1.6500 at the previous close.

    Emmaus stock recorded 21.01K shares versus 10.69K for the 30-day Average Volumes. Emmaus stock value ranged from $0.7001 to $2.1600 in the last 52 weeks. EMMA stock rose after marketing authorization application was submitted.

    The application was for what?

    Emmaus is a biopharmaceutical company focused on discovering, developing, marketing, and selling treatments for rare and orphan diseases.

    Emmaus recently announced that the Saudi Food and Drug Authority (SFDA) has accepted its application for Marketing Authorization (MA) for Endari in Saudi Arabia.

    Typically, the SFDA’s MA approval and review process takes between 12 and 18 months. The United States Food and Drug Administration has approved Endari, an oral supplement of L-glutamine that Emmaus offers to treat sickle cell anemia in adults and pediatric patients ages five and older.

    EMMA’s further plans:

    The submission and approval of the marketing authorization application for Emmaus (EMMA) by the Saudi Food & Drug Authority is another milestone in its progress and commitment to serve sickle cell disease patients across the Middle East and North African region.

    Throughout the Kingdom of Saudi Arabia, EMMA maintains and enhances relationships with hematologists and patients rights groups. As part of the collaboration with clinicians, Emmaus is working to provide Endari on an individual patient basis in the Kingdom and broader MENA region.

  • Has CGEI Stock Risen 60% For A Reason?

    CGE Energy Inc (OTCPk-CGEI) stock surged to $2.400 at yesterday’s close, representing a 60.00% gain. Last week, CGE Energy stock’s performance exceeded 242% compared to its performance of 220% over the past month. Due to CGEI stock price rise in the absence of current news, recent developments can be used to analyze the company in greater depth.

    How did things go recently at CGEI?

    As an energy developer and self-powered infrastructure owner and operator, CGE Energy and its wholly-owned subsidiary Clean Green Energy, Inc. develop sustainable energy projects over the long term. With CGEI, businesses, municipalities, and nonprofits can resolve their energy challenges. Through the use of their energy services and products, CGEI customers are able to save energy, reduce costs, reduce emissions and take advantage of environmental benefits.

    According to CGE Energy, its subsidiary Aradatum has made significant strategic moves and plans to publicly detail its roll-out plans within the next few months.

    • At the moment, Adaatum is scaling up, creating a pre-sales network in anticipation of deliveries beginning in 2022, preparing the towers for commercial manufacture, and speaking with potential investors.
    • These moves are on the horizon for the market and short interest.
    • Short interest has dropped significantly.
    • CGEI has previously said that it plans to spin-off Aradatum at some point in the future to own and operate self-powered cell towers for the telecom and technology industries.

    How CGEI will spin off Aradatum?

    The intention is that upon spin-off, the CGEI Shareholders will receive Aradatum Shares per CGE Share owned as of the last trading day prior to the spin-off, as a result of a one Aradatum Share for every one CGE Share. Shares in Aradatum will only be awarded to CGEI shareholders until the spin-off. Until Aradatum is spun-off, holding CGEI Shares or investing in a large private equity raising is the primary way to own it.

  • Do You Know Why Nexteer (NTXVF) Stock Jumped 14%?

    As of Friday, the leader in intuitive motion control Nexteer Automotive Group Ltd. (OTCPK: NTXVF) had closed at $1.2000, up 13.85 percent trading within a range of $1.2000 to $1.2160 on the day. The Nexteer stock has experienced a 130.77% gain over the past year, reaching a high of $1.9300 with a $3 billion market cap. NTXVF stock spiked after winning an award.

    What was that award for?

    Nexteer Automotive is a global leader in intuitive motion control. As a multi-billion dollar global steering and driveline company, NTXVF brings electric and hydraulic power steering systems, steering columns, and drivetrain systems to market. A major part of NTXVF’s business is the development of automated driving technologies for original equipment manufacturers (OEMs) and advanced driving assistance systems (ADAS). In addition to its 27 manufacturing plants, NTXVF has four technical and software centers, as well as 13 customer service centers spread throughout North and South America, Europe, Asia, and Africa.

    IDG’s CSO 100 program has named Nexteer an honoree for the CSO50 Award for 2021. A select group of organizations are awarded this award for implementing business-value-driven security projects and initiatives.

    One of Nexteer’s winning projects, NEXTINTRUST, provides Internet of Things (IoT), Operational Technology (OT) efforts, as well as asset visibility and security. In addition to providing complete visibility into all Nexteer devices, NEXTINTRUST enables Nexteer to identify the risks these devices pose as well as develop policies to secure them.

    How this will help NTXVF?

    In combination with Operational Technologies, Internet of Things networks bring significant changes regarding how systems that were traditionally linked are connected today. NEXTINTRUST lets Nexteer (NTXVF) enact proactive control strategies by validating identities, integrating insights, and controlling the use of layered security architecture.

  • Is This Why The Synairgen (SYGGF) Stock Rose Last Trading?

    Is This Why The Synairgen (SYGGF) Stock Rose Last Trading?

    Synairgen plc (OTCPINK: SYGGF) closed up 14.98 percent on Friday at $2.3110, trading in a range of $2.15 to $2.39 throughout the day. Synairgen stock rose more than 12.46 percent during the last month and averaged 10.28K shares during that time. SygGF’s stock rose following positive in vitro results.

    The studies were for what?

    Sir Stephen Holgate, Donna Davies, and Ratko Djukanovic founded Synairgen as a clinical-stage respiratory drug discovery and development company. A current focus of SYGGF is on the development of its product candidate SNG001 (inhaled interferon beta) for the treatment of COVID-19.

    A new antiviral treatment from Synairgen, SNG001, maybe the first to deliver broad-spectrum antivirals directly into the lungs. NIHR’s National Institute for Health Research (NIHR) has determined that SNG001 nebulized therapy is an urgent public health study, and SYGGF is evaluating this treatment in its Phase III clinical program.

    Earlier last week, Synairgen announced that its antiviral treatment SNG001 was active against both SARS-CoV-2 strains in-vitro studies.

    The natural antiviral response of the body is delivered by interferon-beta (‘IFN-beta’), which is produced by the activation of hundreds of antiviral proteins that act throughout the viral replication cycle to confer broad-spectrum antiviral protection. In order to prevent infection of the lower respiratory tract by the SARS-CoV-2 virus, SNG001 is nebulised directly into the lungs of patients. 

    These results have confirmed SYGGF’s belief that SNG001 is a broad-spectrum antiviral agent, demonstrating even more application to SARS-CoV-2 variants than earlier thought. It is planned that Synairgen (SYGGF) will start dosing patients at phase III trial sites in India in the near future.